Treatment of viral and infectious diseases using an inhibitor of cbp/catenin

An alpha helix mimetic β-catenin inhibitor compound for the treatment of viral and infectious diseases, having the following formula (I):

• wherein:
• A is —CHR7—,
• wherein R7 is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl;
• G is —NH—, —NR6—, —O—, —CHR6— or —C(R6)2—,
• wherein R6 is independently selected from optionally substituted alkyl, optionally substituted alkenyl and optionally substituted alkynyl;
• R1 is optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted cycloalkylalkyl or optionally substituted heterocycloalkylalkyl;
• R2 is —W21—W22—Rb—R20,
• wherein W21 is —(CO)— or —(SO2)—;
• W22 is bond, —O—, —NH— or optionally substituted lower alkylene;
• Rb is bond or optionally substituted lower alkylene;
• and R20 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted heterocycloalkyl;
• and
• R3 is optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;
• or a pharmaceutically acceptable salt thereof.